Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hospital Mater Dei S.A (MATD3) Fair Value & Analysis

Healthcare · BR · Market cap R$1.6B

PriceR$4.71
Fair ValueR$7.33
Upside+55.6%
Quality95/100
Evidence: High Range R$5.14 – R$9.17

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Hospital Mater Dei S.A (MATD3) currently trades at R$4.71, while our model-based Fair Value estimate is R$7.33 — implying the stock looks roughly 55.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Hospital Mater Dei S.A. operates hospitals in Brazil. It engages in data and artificial intelligence business. The company was incorporated in 1973 and is headquartered in Belo Horizonte, Brazil. Hospital Mater Dei S.A. is a subsidiary of JSS Empreendimentos e Administração LTDA.

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) +19% Fresenius SE (FSNUY) -25% 5225 (5225) -70% IHHHF (IHHHF) -57% Rede D'Or São Luiz S.A (RDOR3) -7% Tenet Healthcare Corporation (THC) +86%

Frequently asked questions

Is Hospital Mater Dei S.A (MATD3) undervalued?
As of Jun 25, 2026, our model estimates a fair value of R$7.33 versus a price of R$4.71 — about +56% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MATD3?
Our 21-model fair value for Hospital Mater Dei S.A is R$7.33 (as of Jun 25, 2026), built from audited fundamentals. The current price is R$4.71.
What is the quality score of MATD3?
Hospital Mater Dei S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.